文献速递炎症性肠病

生物制剂初治的克罗恩病患者腹腔内脓肿消退后使用阿达木单抗:一项来自GETAID的前瞻性研究

Adalimumab in Biologic-naïve Patients With Crohn's Disease After Resolution of an Intra-abdominal Abscess: A Prospective Study From the GETAID.
PubMed 文献 · Clin Gastroenterol Hepatol · 2023-01-31

这项多中心前瞻性研究纳入117例生物制剂初治、腹腔内脓肿已消退的克罗恩病患者,随访2年。第24周74%的患者达到阿达木单抗治疗成功,第104周无脓肿复发或手术的生存率为72.9%。脓肿引流与第24周及第104周治疗失败显著相关。

要点

  • 生物制剂初治的克罗恩病患者腹腔内脓肿消退后使用阿达木单抗,第24周治疗成功率为74%。
  • 第104周无脓肿复发或手术的生存率为72.9%。
  • 脓肿引流与第24周及第104周阿达木单抗治疗失败显著相关。

核心结论

  • 在开始药物治疗前对脓肿进行仔细管理的前提下,本研究显示阿达木单抗在生物制剂初治、并发腹腔内脓肿的克罗恩病患者中短期和长期均具有高效性。

研究设计与样本

  • 多中心、前瞻性研究,在生物制剂初治的克罗恩病合并腹腔内脓肿已消退的患者中进行,随访2年。
  • 2013年4月至2017年12月从27个GETAID中心筛查190例患者,最终117例纳入分析。
  • 主要终点为第24周阿达木单抗治疗失败,定义为第12周后需要使用类固醇、肠切除、脓肿复发和临床复发。
  • 次要事后终点为长期成功,定义为第104周时无脓肿复发或肠切除的生存。

主要发现

  • 117例患者中58例(50%)为男性,基线中位年龄为28岁。
  • 第24周时,87例患者(74%;95%CI 65.5%-82.0%;n=117)达到阿达木单抗治疗成功。
  • 30例阿达木单抗治疗失败的患者中,15例接受了手术。
  • 第104周时,无脓肿复发或手术的生存率为72.9%(95%CI 62.1%-79.8%;n=109)。
  • 脓肿引流与第24周阿达木单抗治疗失败显著相关(OR 4.18;95%CI 1.06-16.5;P=0.043);病程(HR 1.32;95%CI 1.09-1.59;P=0.008)、脓肿引流(HR 5.59;95%CI 2.21-14.15;P=0.001)及肠系膜脂肪炎性改变(HR 0.4;95%CI 0.17-0.94;P=0.046)与第104周阿达木单抗治疗失败显著相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: The management of intra-abdominal abscesses complicating Crohn's disease (CD) is challenging, and surgery with delayed intestinal resection is often recommended. The aims of this study were to estimate the success rate of adalimumab (ADA) in patients with CD with an intra-abdominal abscess resolved without surgery, and to identify predictive factors for success. METHODS: A multicenter, prospective study was conducted in biologic-naïve patients with CD with resolved intra-abdominal abscess treated with ADA with a 2-year follow-up. The primary endpoint was ADA failure at week (W) 24 defined as a need for steroids after W12, intestinal resection, abscess recurrence, and clinical relapse. Secondary post-hoc endpoint was the long-term success defined as the survival without abscess relapse or intestinal resection at W104. The factors associated with ADA failure at W24 and W104 were identified using a logistic and a Cox regression, respectively. RESULTS: From April 2013 to December 2017, 190 patients from 27 GETAID centers were screened, and 117 were included in the analysis. Fifty-eight patients (50%) were male, and the median age at baseline was 28 years. At W24, 87 patients (74%; 95% confidence interval [CI], 65.5%-82.0%; n = 117) achieved ADA success. Among the 30 patients with ADA failure, 15 underwent surgery. At W104, the survival rate without abscess recurrence or surgery was 72.9% (95% CI, 62.1%-79.8%; n = 109). Abscess drainage was significantly associated with ADA failure at W24 (odds ratio, 4.18; 95% CI, 1.06-16.5; P =0 .043). Disease duration (hazard ratio [HR], 1.32; 95% CI, 1.09-1.59; P = .008), abscess drainage (HR, 5.59; 95% CI, 2.21-14.15; P = .001), and inflammatory changes in mesenteric fat (HR, 0.4; 95% CI, 0.17-0.94; P = .046) were significantly associated with ADA failure at W104. CONCLUSION: Provided that the abscess was carefully managed before initiating medical treatment, this study showed the high efficacy of ADA in the short and long term in biologic-naïve patients with CD complicated by an intra-abdominal abscess. CLINICALTRIALS: gov, Number: NCT02856763.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Bouhnik Y, Pineton de Chambrun G, Lambert J, et al. Adalimumab in Biologic-naïve Patients With Crohn's Disease After Resolution of an Intra-abdominal Abscess: A Prospective Study From the GETAID. Clin Gastroenterol Hepatol. 2023. PMID: 36731588. doi:10.1016/j.cgh.2023.01.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。